Communiqués Intensity Therapeutics, Inc.

Actions

INTS

US45828J2024

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:30:00 14/08/2026			Varia. 5j.	Varia. 1 janv.
3,960 ^USD	-1,00%		-4,81%	-61,38%

11/08	Intensity Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
11/08	Transcript : Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026

Communiqués

12/08	Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
04/08	Intensity Therapeutics : to Announce Second Quarter 2026 Financial Results on August 11, 2026	PU
15/07	Intensity Therapeutics : Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)	PU
08/05	Intensity Therapeutics : Reports First Quarter 2026 Financial Results and Provides Corporate Update	PU
27/03	Intensity Therapeutics : Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update	PU
12/03	Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study	PR
06/03	Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement	PR
13/02	Intensity Therapeutics Announces Reverse Stock Split	PR
13/01	Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities	PR
18/12	Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Clinical Trial	PU
18/12	Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations	PU
11/12	Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium	PR
08/12	Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement	AQ
05/12	Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement	PR
06/11	Intensity Therapeutics : Reports Third Quarter 2025 Financial Results and Provides Corporate Update	PU
31/10/25	Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock	PR
02/09/25	Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference	PR
12/08/25	Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement	PR
07/08/25	Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update	PR
04/08/25	Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025	PR
30/06/25	Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)	PR
12/06/25	Intensity Therapeutics, Inc. Announces Pricing of Public Offering	PR
11/06/25	Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock	PR
11/06/25	Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study	PR
02/06/25	Hypothesis: In a randomized controlled study, Intratumoral INT230-6 dosed alone into a few large tumors will increase overall survival for patients with metastatic sarcomas compared to the best systemic, standard-of-care therapies	PU